Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

BACKGROUND: Several therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to make informed treatment decisions. Herein we characterize adjuvant nivolumab select (immune-related) treatment-related adverse events (TRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandalá, Mario, Larkin, James, Ascierto, Paolo A, Del Vecchio, Michele, Gogas, Helen, Cowey, C Lance, Arance, Ana, Dalle, Stéphane, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O, Di Giacomo, Anna Maria, Lutzky, Jose, De La Cruz-Merino, Luis, Atkinson, Victoria, Arenberger, Petr, Hill, Andrew, Fecher, Leslie, Millward, Michael, Khushalani, Nikhil I, de Pril, Veerle, Lobo, Maurice, Weber, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404438/
https://www.ncbi.nlm.nih.gov/pubmed/34452930
http://dx.doi.org/10.1136/jitc-2021-003188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404438/
https://www.ncbi.nlm.nih.gov/pubmed/34452930
http://dx.doi.org/10.1136/jitc-2021-003188

Ejemplares similares